Money Concepts Capital Corp Has $8.36 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Money Concepts Capital Corp reduced its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 90,538 shares of the biopharmaceutical company’s stock after selling 3,776 shares during the period. Money Concepts Capital Corp’s holdings in Gilead Sciences were worth $8,363,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. nVerses Capital LLC bought a new stake in Gilead Sciences during the 3rd quarter worth approximately $25,000. HHM Wealth Advisors LLC increased its stake in shares of Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 154 shares in the last quarter. Valued Wealth Advisors LLC lifted its position in Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 161 shares in the last quarter. Decker Retirement Planning Inc. bought a new stake in Gilead Sciences during the 4th quarter worth about $29,000. Finally, Crews Bank & Trust bought a new position in shares of Gilead Sciences in the fourth quarter worth about $31,000. Institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 142,180 shares of Gilead Sciences stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $97.22, for a total value of $13,822,739.60. Following the completion of the transaction, the chief financial officer now owns 129,873 shares of the company’s stock, valued at $12,626,253.06. This trade represents a 52.26 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jeffrey Bluestone sold 6,788 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the sale, the director now owns 8,920 shares of the company’s stock, valued at $815,198.80. This trade represents a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 572,824 shares of company stock valued at $53,611,715. 0.29% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts recently weighed in on GILD shares. Oppenheimer boosted their price objective on shares of Gilead Sciences from $105.00 to $115.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 10th. Bank of America reissued a “buy” rating and set a $109.00 price objective on shares of Gilead Sciences in a report on Tuesday, December 10th. Wells Fargo & Company raised their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. UBS Group boosted their price target on shares of Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a research note on Thursday, November 21st. Finally, Sanford C. Bernstein began coverage on shares of Gilead Sciences in a report on Thursday, October 17th. They set an “outperform” rating and a $105.00 target price for the company. Eleven investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $98.39.

Gilead Sciences Trading Down 0.4 %

Shares of NASDAQ:GILD opened at $97.99 on Wednesday. The stock has a market capitalization of $122.12 billion, a PE ratio of 1,088.78, a price-to-earnings-growth ratio of 1.37 and a beta of 0.18. The company’s 50-day moving average price is $92.71 and its two-hundred day moving average price is $86.32. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $99.45.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.29 earnings per share. On average, equities analysts forecast that Gilead Sciences, Inc. will post 4.34 EPS for the current fiscal year.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.